-
-
-
-
-
-
-
Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
-
-
-
-
-
-
-
Vertex Pharma (VRTX) Reports Results From Phase 2 Study of Suzetrigine
-
-
-
-
-
-
-
Vertex to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting
-
-
-
-
-
-
-
Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain
-
-
-
-
-
-
-
Vertex Pharma (VRTX) Presents Positive Results from Pivotal Trials of CASGEVY
-
-
-
-
-
-
-
Vertex Reports Second Quarter 2023 Financial Results
-
-
-
-
-
-
-
Vertex Reports Second Quarter 2022 Financial Results
-
15,546 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

